Aurobindo Pharma Limited has provided clarification to stock exchanges regarding significant volume movement in its shares, linking the activity to recent government policy changes affecting the pharmaceutical sector. The company issued the clarification on January 31, 2026, in response to queries from the National Stock Exchange of India Limited dated January 30, 2026.

Government MIP Notification Impact

The pharmaceutical company highlighted that the Government of India notified the imposition of Minimum Import Price (MIP) on January 29, 2026, covering specific pharmaceutical compounds. The notification applies to imports intended for domestic consumption and includes three key substances.

Company's Manufacturing Connection

Aurobindo Pharma's wholly owned subsidiary, Lyfius Pharma Private Limited, is engaged in manufacturing Penicillin-G and downstream derivatives, directly connecting the company to the products covered under the MIP notification. This manufacturing involvement explains the market's interest in the company's shares following the government announcement.

Regulatory Compliance and Disclosure

The company emphasized its commitment to regulatory compliance and transparency in its communication to the exchanges. Aurobindo Pharma confirmed that it has been making timely and adequate disclosures of all material events and information in strict compliance with SEBI regulations.

Key compliance aspects include:

• Adherence to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
• Timely disclosure of material events and information
• Continuous compliance with disclosure obligations

Market-Driven Volume Movement

The company attributed the recent increase in trading volume to market-driven factors, noting that information about the MIP notification was already in the public domain through the government's DGFT website. Aurobindo Pharma clarified that there was no company-specific information requiring separate disclosure, as the policy announcement was a general government notification affecting the industry.

The pharmaceutical company confirmed that as of the clarification date, there were no other pending announcements or information that could impact the price or volume movement of its securities. This statement provides transparency to investors regarding potential future developments that might affect share performance.

Source:

Aurobindo Pharma Limited has established a new wholly owned subsidiary in the Philippines as part of its international expansion strategy. The pharmaceutical company announced the incorporation of Aurobindo Pharma Philippines Inc. on January 23, 2026, through its existing subsidiary structure.

Subsidiary Structure and Ownership

The new Philippine entity has been incorporated as a wholly owned subsidiary of Helix Healthcare B.V., which is based in the Netherlands and serves as a wholly owned subsidiary of Aurobindo Pharma Limited. This creates a step-down subsidiary structure that enables the company to expand its operations in the Southeast Asian market.

Financial Investment and Share Capital

The newly incorporated subsidiary has been established with substantial initial funding to support its operations in the Philippines market. The company has made a complete cash subscription to the share capital structure.

Business Objectives and Market Expansion

The primary objective behind establishing Aurobindo Pharma Philippines Inc. is to expand the company's pharmaceutical products business in the Philippines. This strategic move aligns with the company's core pharmaceutical operations and represents a natural extension of its existing business model into new geographic markets.

The subsidiary will operate in the pharmaceuticals industry, focusing on expanding the reach of Aurobindo Pharma's product portfolio in the Philippine market. As a newly incorporated entity, the company does not have historical turnover data, but it is positioned to leverage the parent company's extensive pharmaceutical expertise and product range.

Regulatory Compliance and Approvals

The incorporation process was completed without requiring any governmental or regulatory approvals, indicating a streamlined establishment process. The transaction has been structured as a related party transaction due to the subsidiary relationship, though promoters and the promoter group of Aurobindo Pharma Limited have no direct interest in this particular transaction.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders and regulatory authorities. This regulatory filing demonstrates the company's commitment to maintaining proper corporate governance standards in its expansion activities.